Vemurafenib — Drug Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

7 Recruiting

4 Completed trials

10 Sponsors

17 Countries

Phase II

Phase III: 1 Phase II: 9 Phase IV: 1

Oversight events:

1 serious breach 2 urgent safety measures across 2 trials

View oversight register →

Indications tested

Rosai-Dorfman syndrome 1 Erdheim-Chester disease 1 Non-small cell lung cancer 1 Renal cell carcinoma 1 Triple negative breast cancer 1 Langerhans' cell histiocytosis 1 Squamous cell carcinoma of head and neck 1 Langerhans cell sarcoma 1 Ovarian cancer 1 Skin cancer 1 Hairy cell leukaemia 1 Non-small cell lung cancer stage IV 1

Sponsors using this IMP

Universita' Degli Studi Di Perugia 2 F. Hoffmann-La Roche AG 1 Fondazione Melanoma Onlus 1 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 1 HUS-Yhtymae 1 Instytut Matki I Dziecka 1 Oslo University Hospital HF 1 Pfizer Inc. 1 Rigshospitalet 1 Unicancer 1

All trials

11 total

FINPROVE - The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Recruiting

2024-517478-68-01 Phase II 1 country HUS-Yhtymae
VEMURAFENIB PLUS RITUXIMAB AS A CHEMOTHERAPY-FREE ALTERNATIVE TO CLADRIBINE FOLLOWED BY MRD-GUIDED RITUXIMAB IN FRONT-LINE HAIRY CELL LEUKEM… Recruiting

2024-520119-41-00 Phase II 1 country Universita' Degli Studi Di Perugia
To check the safety, efficacy and tolerability of the drug vemurafenib, and to determine the duration of treatment in children with BRAF mut… Recruiting

2024-515805-25-00 Phase II 1 country Instytut Matki I Dziecka
Improving public cancer care by implementing precision medicine in Norway Recruiting

2023-507894-16-00 Phase II 1 country Oslo University Hospital HF
“A phase II randomized non-comparative study, with NEOadjuvant plus adjuvant Therapy with combination or sequence of vemurafenib, cobImetini… Recruiting

2024-516659-41-00 Phase II 1 country Fondazione Melanoma Onlus
ProTarget - A Danish Nationwide Clinical Trial on Targeted Anti‐Cancer Treatment based on Genomic Profiling Recruiting

2023-510527-29-00 Phase II 1 country Rigshospitalet
DRUP trial Recruiting

2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
STEP-WISE COMBINATION OF OBINUTUZUMAB, VEMURAFENIB AND COBIMETINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) PREVIOUSLY TREATED WITH PURINE… Ended

2024-520121-36-00 Phase II 1 country Universita' Degli Studi Di Perugia
Master Protocol for Encorafenib/Binimetinib Continuation Sub-Studies (FLOTILLA Study) Ended

2023-509408-13-00 Phase IV 9 countries Pfizer Inc.
An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizu… Ended

2023-506184-34-00 Phase III 11 countries F. Hoffmann-La Roche AG
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations Ended

2024-514904-14-00 Phase II 1 country Unicancer

Showing 1–11 of 11 trials

← All drugs A–Z